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Abstract
Background-: Although the therapeutic potential of bone marrow-derived stromal stem cells (BMSC) has been
demonstrated in different experimental models of ischemic stroke, it remains unclear how stem cells (SC) induce
neuroprotection following stroke. In this study, we describe a novel method for isolating BMSC that infiltrate
postischemic brain tissue and use this method to identify the genes that are persistently activated or depressed in
BMSC that infiltrate brain tissue following ischemic stroke.
Methods-: Ischemic strokes were induced in C57BL/6 mice by middle cerebral artery occlusion for 1 h, followed by
reperfusion. BMSC were isolated from H-2 Kb-tsA58 (immortomouse™) mice, and were administered (i.v.) 24 h after
reperfusion. At the peak of therapeutic improvement (14 days after the ischemic insult), infarcted brain tissue was
isolated, and the BMSC were isolated by culturing at 33°C. Microarray analysis and RT-PCR were performed to compare
differential gene expression between naïve and infiltrating BMSC populations.
Results-: Z-scoring revealed dramatic differences in the expression of extracellular genes between naïve and
infiltrating BMSC. Pair-wise analysis detected 80 extracellular factor genes that were up-regulated (≥ 2 fold, P < 0.05,
Benjamini-Hochberg correction) between naïve and infiltrated BMSC. Although several anticipated neuroregenerative,
nerve guidance and angiogenic factor (e.g., bFGF, bone morphogenetic protein, angiopoietins, neural growth factor)
genes exhibited an increased expression, a remarkable induction of genes for nerve guidance survival (e.g., cytokine
receptor-like factor 1, glypican 1, Dickkopf homolog 2, osteopontin) was also noted.
Conclusions-: BMSC infiltrating the post-ischemic brain exhibit persistent epigenetic changes in gene expression for
numerous extracellular genes, compared to their naïve counterparts. These genes are relevant to the neuroprotection,
regeneration and angiogenesis previously described following stem cell therapy in animal models of ischemic stroke.
Background
In various animal models of central nervous system
(CNS) injury, bone marrow stromal cells (BMSC) have
been reported to be effective in limiting tissue damage[14]. The therapeutic effects of stem cells have been attributed to their ability to release of a mixture of neurotrophins, growth factors, and other substances that induce
restorative processes in post-ischemic brain tissue[1,5-8].
Although some studies have focused on the role of one or
more potential neuroprotective factors that are released
from BMSC, less effort has been made to evaluate the
responses of BMSC once they infiltrate brain tissue following an ischemic insult[7,9].
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Immortalized cell lines have long been used as a source
of stem cells for in vivo studies of the therapeutic efficacy
of stem cells in models of ischemic tissue injury[10-12].
While these cells have been shown to survive and differentiate in brain tissue and to afford some protection
against ischemic stroke, they are difficult to recover from
brain tissue to permit assessment of the phenotypic and
genetic changes that underlie their protective actions.
Immortalized BMSC isolated from the H-2Kb-tsA58
transgenic mouse express a gene for temperature sensitive conditional immortality that makes them a more
suitable model for stem cell recovery in ischemic tissue[13]. Stem cells from this background exhibit stem cell
marker characteristics for over a year[13] and can give
rise to cells of the mesenchymal lineage [14]. A particularly advantageous characteristic of BMSC from the H-2
Kb-tsA58 transgenic strain, is that the cells are undiffer-
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entiated at 33°C, but will acquire a differentiated phenotype at 37°C to yield a large number of cells with stem cell
properties.
Although it is widely accepted that stem cells administered in animal models of stroke selectively home to and
infiltrate the site of brain injury[14,15], successful isolation and genetic evaluation of these cells after they have
infiltrated the post-ischemic brain has not been reported
to date. In this study, we employed immortalized BMSC
from H-2 Kb-tsA58 mice to selectively isolate stem cells
that infiltrate brain tissue and produce therapeutic benefit following focal ischemia and reperfusion. The infiltrating BMSC were probed using whole genome array and
RT-PCR in order to identify genes that are persistently
up- or down-regulated in the stem cells after their
appearance in infarcted brain tissue.

Methods
Animals

All in vivo experiments were performed on male C57Bl/
6J mice (WT; 6 to 8 weeks old) (Jackson Laboratories, Bar
Harbor, Me). BMSC were isolated from either H-2KbtsA58 mice expressing temperature-sensitive SV40 large
T antigen (Large T; CBA/ca × C57Bl/10 hybrid, Charles
River Laboratories) or from WT mice. The experimental
procedures employed in this study were approved by the
Louisiana State University Health Sciences Center Institutional Animal Care and Use Committee and are in
compliance with the guidelines of National Institutes of
Health.
BMSC isolation

Primary cultures of BMSC were obtained from WT or
Large T mice as previously described[16]. Briefly, fresh
complete bone marrow was harvested aseptically from
the tibias and femurs and then cultured in Iscove's Modified Dulbecco's medium (IMDM) supplemented with
10% fetal bovine serum (FBS). BMSC isolated from Large
T mice were cultured at 33°C for selective isolation of the
immortalized cells. After 3 days of incubation, nonadherent cells were removed and cells tightly adhered to
plastic were isolated and resuspended to fresh Iscove's
Modified Dulbecco's medium in new flasks for further
growth. By passage 3, less than 1% of cells were positive
for CD11b and CD45 as assessed by flow cytometry, and
the BMSC were stem cell antigen-1 (sca-1) positive (70%).
Prior to use in the in vivo model, BMSC were harvested
using a non-enzymatic dissociation solution (Sigma
Chemicals, St Louis), centrifuged at 1000 × g, filtered
through a 70 um cell strainer (BD, Falcon), and resuspended in PBS (pH 7.4). 2 × 106 viable WT or Large T
BMSC(in 150 μl of PBS) or PBS (150 μl) were administered intravenously at 24 hours after the induction of
cerebral ischemia.
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Middle cerebral artery (MCA) occlusion and reperfusion
(MCAo/R)

The mice were anesthetized by intraperitoneal injection
of ketamine (50 mg/kg) and xylazine (2.5 mg/kg). Transient (60 minutes) focal cerebral ischemia was induced by
occlusion of the left middle cerebral artery (MCAo) using
a modification of intraluminal filament method. Briefly,
the blunted tip of a 6-0 nylon monofilament was
advanced to the level of the carotid bifurcation via the
internal carotid artery until light resistance was felt. The
distance from the nylon thread tip to the internal carotid
artery-pterygopalatine artery bifurcation was slightly
greater than 6 mm, and the distance to the bifurcation of
the internal and external carotid arteries was slightly less
than 9 mm. The monofilament was removed after 60
minutes of occlusion. In the sham group, these arteries
were visualized but not disturbed. Ischemia and reperfusion (I/R) were verified using a Laser Doppler flowmeter
probe (MSP300XP, AD Instruments Inc.) attached to the
left parietal cranium. At the end of experiments, mice
were killed with a lethal dose of pentobarbital (150 mg/
kg, i.p.). The brains were immediately removed, and then
stained with 2% 2, 3, 5-triphenyltetrazolium chloride to
confirm the production of an infarct.
Neurological score

In another set of experiments, the therapeutic effects of
SC were assessed in mice receiving either 2 × 106 viable
WT SC or Large T SC (in 150 μl of PBS) or PBS (150 μl)
intravenously at 24 hours after the induction of cerebral
ischemia. The neurological outcome was assessed at 1, 7
and 14 days after administration of SC using a 5-point
scale neurological deficit score (0 = no deficit, 1 = failure
to extend right paw, 2 = circling to the right, 3 = falling to
the right, 4 = unable to walk spontaneously)[17].
Recovery of Large T BMSC from ischemic brains

Mice were sacrificed 14 days after BMSC administration
with a lethal dose of pentobarbital (150 mg/kg, i.p.). Ischemic hemispheres were removed from recipient mice that
received either WT or Large T BMSC. The infarcted
cerebral hemisphere was cut into small pieces and incubated with 2% collagenase at 37°C for 2 hours. The collagenase treated hemispheres were centrifuged at 1500
RPM for 10 min. The supernatants were discarded and
tissues were resuspended in IMDM with 10% FBS and 1%
streptomycin/penicillin. The suspensions were filtered
through a 70-μm cell strainer (BD Falcon) and the filtered
fractions were plated into 75 cm2 flasks, cultured at 33°C
in a mixture of 5% carbon dioxide and 95% oxygen, with
the media replaced as needed. The cells isolated from
ischemic brain tissue of mice receiving Large T BMSC
reached confluency in 7 - 10 days. However, no cell
growth was detected when infarcted tissue derived from
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mice receiving either WT BMSC or saline was cultured at
33°C under identical culture conditions.
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Immortalized stem cells (~104 cells) were adhered onto
1.2 cm diameter coverslips by centrifugation at 1,500 × g
for 15 min in culture medium. Coverslips were then fixed
in 1% paraformaldehyde in PBS (30 min), and extracted in
0.2% Triton-X100/PBS (5 min). Permeabilized coverslips
were incubated for 1 h in 75 ul of mouse anti-SV40 large
TAg (1:150), (pab416; ts A58, AbCAM, Cambridge, MA)
in 0.1% milk powder in PBS (MPBS) at 25°C. Coverslips
were washed 3-times in 0.1% MPBS, and then incubated
with 75 ul of goat anti-mouse fluorescein conjugated antibody (1:50) in MPBS (1 h). After 3 washes in 0.1% MPBS,
coverslips were mounted in 1:5 diluted Vectashield/DAPI
(Vector Labs, Burlingame, CA) and sealed with nail polish. Using fluorescence microscopy (Olympus AX70
microscope), the BMSC were examined for fluorescein
(SV40 large Tag) and nuclei (DAPI), and the images captured with a Nikon Coolpix camera.

Arrays were then stained once again with streptavidin-R
phycoerythrin for 10 min at 25°C. After washing and
staining, the arrays were scanned using a GeneChip Scanner 3000. Pixel intensities were measured, expression signals were analyzed and features extracted using the
commercial software package GeneChip Operating Software 1.2 (Affymetrix).
Three independent sets of experiments were performed, each containing RNA samples pooled from
BMSC populations isolated from 3 ischemic hemispheres
or 3 sets of naïve Large T SC. Data mining and statistical
analysis were performed with genesifter.net software. A
two-fold or more change in gene expression with an
unpaired t-test corrected with the Benjamini-Hochberg
procedure[18], and a p < 0.05 was considered significant
and used for further analysis. The Z-score was used to
detect the most affected gene ontology families, with a
high Z-score indicating a highly affected pathway[19].
Genes related to molecular function, localization and
biological processes were analyzed by gene ontology
detecting software http://www.genesifter.net.

Gene microarray

Real time quantitative PCR

Pair-wise gene expression analysis was performed to
compare the differences in gene expression patterns of
naïve Large T (cell population injected into mice) with
the Large T cell population isolated from infarcted tissue
(iLarge T). RNA was extracted from cells using
QIAshredder (Qiagen, Hilden, GmbH) and an RNeasy
mini kit (Qiagen, Maryland), according to manufacturer's
directions. RNA integrity was assessed by electrophoresis
on the Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA). Double-stranded cDNA was synthesized
from approximately 7 ug total RNA, using a Superscript
cDNA Synthesis Kit (Invitrogen, Carlsbad, CA) in combination with a T7-(dT)24 primer (Proligo, Boulder, CO).
Biotinylated cRNA was transcribed in vitro using the BioArray High Yield RNA Transcript Labeling Kit (ENZO
Biochem, New York, NY) and purified using the
GeneChip Sample Cleanup Module (Affymetrix, Santa
Clara, CA). Twenty micrograms of purified cRNA was
fragmented by incubation in fragmentation buffer (200
mM Tris-acetate, pH 8.1, 500 mM potassium acetate, 150
mM magnesium acetate) at 94°C for 35 minutes and
chilled on ice. Ten micrograms of fragmented biotinlabeled cRNA was hybridized to the Mouse Genome 430
2.0 Array (Affymetrix), interrogating over 39,000 transcripts. Arrays were incubated for 16 hr at 45°C with constant rotation (60 rpm). The arrays were washed and then
stained for 10 min at 25°C with 10 ug/mL streptavidin-R
phycoerythrin (Vector Laboratories, Burlingame, CA)
followed by 3 ug/mL biotinylated goat anti-streptavidin
antibody (Vector Laboratories) for 10 minutes at 25°C.

Total RNA extracted from naïve and iLarge T SC was
used as a template for cDNA synthesis. For each sample,
100 ng of total RNA was used as a template for cDNA
synthesis. The reverse transcription reaction was performed in master mix containing RT buffer, MgCl2,
dNTPs, random hexamers, RNase inhibitor and multiscribe reverse transcriptase (Applied Biosystems, Foster
City, CA). Incubations were performed in a Mastercyclerpersonal (Eppendorf, Westbury, NY) for 10 min at room
temperature followed by 60 min at 42 C and 5 min at 95
C. For quantitative real-time PCR analysis the primers
listed in Table S1, Additional file 1 were used (Realtime
Primers, Elkins Park, PA). Fast SYBR Green master mix
was used for amplification and detection. Reactions were
performed in triplicate using an ABI Prism 7900
Sequence Detection System. Raw data were analyzed
using the ABI Prism Sequence Detection 1.9.1 software.
The comparative Cr method for relative quantification of
gene expression was used to determine expression levels
for target genes. Beta-actin was used as a housekeeping
gene.

Immunostaining of Large T antigen (TAg)

Results
Large-T BMSC improve neurological outcome after MCAO

Intravenous administration of 2 × 10 6 Large T BMSC
after 1 hour of cerebral ischemia and 24 hrs reperfusion
blunted the neurological deficits (improved the neurological scores) normally noted in untreated mice two weeks
thereafter (Figure 1). The protective effect of Large T
BMSC was comparable to that observed in mice treated
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BMSC isolated from post-ischemic brain tissue exhibit an
altered gene expression pattern compared to their naive
counterparts
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14 days

Figure 1 Neurological scores of sham, stroke, stroke +WT BMSC
and stroke + Large T BMSC groups over a two week period after
stroke or sham surgery. * represents significant difference from sham
group (p < 0.05), # represents significant difference from stroke group
(P < 0.05), one-way ANOVA with Tukey's post-hoc test.

with BMSC isolated from wild type mice. Even though an
improvement was observed with administration of WT
BMSC or Large T BMSC at 7 days after ischemic stroke, a
statistical difference was observed only at 14 days after
BMSC administration. No difference in infarct volumes
was observed among untreated stroke group versus the
groups that received either WT-BMSC or Large-T BMSC
(data not shown). These results indicate that Large T
BMSC exhibit similar neuroprotective properties as
BMSC isolated from WT mice.
Viable Large-T BMSC can be recovered from post-ischemic
brain tissue

In order to analyze potential phenotypic changes in
BMSC that are recruited into post-ischemic brain, we
devised a novel approach for tissue isolation of BMSC
that capitalized on the ability of Large T BMSC to grow
under culture conditions at 33°C. Using this approach, we
found that Large T BMSC harvested from post-ischemic
brain tissue and then cultured at 33°C exhibit cell growth
and colony formation, while WT BMSC did not exhibit
these responses under identical experimental conditions.
Immunocytochemical staining confirmed the presence of
intracellular Large T antigen in all cells isolated using this
procedure (Figure 2)

Figure 2 Large T BMSC isolated from ischemic brain. A. Nuclear
DAPI Staining, B. Large T immunostaining of the same sample.

The GeneChip® Mouse Genome 430 2.0 array, covering
over 39,000 transcripts, was used to compare gene
expression between BMSC isolated from infarcted tissue
(iLarge T BMSC) and naïve Large T SC. A pair-wise analysis of three independent experiments revealed a dramatically altered gene expression profile in iLarge T BMSC.
Using filtering criteria of a two-fold or more change in
gene expression with an unpaired t-test corrected with
Benjamini-Hochberg procedure[18] (P < 0.05) a list of
1885 differentially expressed genes were detected (Figure
3). Of this total, 995 genes from iLarge T BMSC exhibited
reduced expression (Table S2, Additional file 2), while
890 genes showed increased expression (Table S3, Additional file 3). Among the highly up-regulated genes
(adjusted p < 0.01), endothelial specific cell molecule-1,
bone morphogenic protein-2, nerve growth factor beta,
olfactomedin-1 were detected. The gene microarray was
validated with RT-PCR. A strong correlation (r2 = 0.93)
between mRNA detected by RT-PCR and the gene
microarray results was observed (Figure 4). The data discussed in this publication have been deposited in NCBI's
Gene Expression Omnibus[20] and are accessible
through GEO Series accession number GSE21393 http://
www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE21393.
Genes in Large-T BMSC that encode factors released into
the extracellular space are highly induced by ischemiareperfusion

A gene ontology analysis was performed on Large T
BMSC using Genesifter.net ontology tools. Z-scoring was
used to identify the most affected pathways in isolated
BMSC. A positive Z-score indicates that more genes than
expected fulfilled the criterion for altered expression in a
certain group or pathway; therefore, that group or pathway is likely to be affected by the imposed condition (e.g.,
ischemia)[21]. Z-scores were detected for up-regulated
transcripts related to biological processes, cellular location and molecular function (Figure 5). A very high Zscore was detected for genes targeting the extracellular
region.
Since previous reports suggest that stem cells likely
exert their beneficial effects through the secretion of
trophic factors that enhance brain repair[22], [23], we
focused our analysis on the extracellular factors that
exhibit altered expression in BMSC isolated from postischemic brains. Eighty extracellular factors were
increased in iLarge T BMSC, compared to their naïve
counterparts (Table S4, Additional file 4). Among the
extracellular factors affected, some have previously been
reported as secreted by BMSC (red highlighting in Table
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Highly Expressed Genes in iLarge-T BMSC
t2, P<0.01
Ddr2, Zic3, Cas1, Srpx2, PSL3, Ngf-b, Bmp2,
Esm-1, Pde10a, Nox4

Highly Suppressed Genes in iLarge-T BMSC
t2, P<0.01
Basonuclin, Gpm6a, Brca1, Tspan8, Smpd3, Rfc4
Cyclin B2, Smpd3

Figure 3 Volcano graph of gene expression changes in BMSC isolated from ischemic brain (Group1) versus naïve BMSC (Group2).

S4, Additional file 4), while others (blue highlighting in
Table S4, Additional file 4) have been associated with
brain ischemia. A KEGG (Kyoto Encyclopedia of Genes
and Genomes) pathway analysis was performed by setting the absolute Z-score above 2 and number of genes in
a set as ≥ 10 (Figure 6). This analysis revealed an up-regulation in genes related to the mitogen-activated protein
kinase (MAPK) and axon guidance pathways, and a
down-regulation of genes in cell division-related pathways. The KEGG diagram for axon guidance pathways in
iLarge T BMSC were consistent with activation of a number of relevant genes, including Eph receptors (mediate

neuronal branching), GTPase activators, and semaphorins (Figure 7).

Discussion
Stem cell therapy has received much attention as a potential post-injury intervention to repair stroke-damaged
brain tissue. While there is limited clinical evidence that
convincingly demonstrates stem cell mediated symptomatic relief in individuals who have suffered a stroke[24],
animals studies suggest that stem cell therapy has the
potential to reverse some of the behavioral deficits that
result from ischemic stroke[1,3,4,25,26]. The success in
animal models has led several laboratories to focus on
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Figure 6 Changes in KEGG pathways in BMSC isolated from ischemic brain. Changes filtered for parameters Z-score > 2 and 10 or
more changed genes in related group.

potential mechanisms that may underlie the neuroprotective effects of stem cell therapy. A limitation of these
mechanistic studies is an inability to isolate and characterize the population of stem cells that infiltrate postischemic brain tissue. Single cell isolation methods, such
as laser capture, have provided some insights, but the low
yield and poor survival of the recovered stem cells limits
the utility of this approach. Here, we introduce a novel
approach for selective isolation of BMSC from infarcted

brain tissue. This approach yields viable infiltrating stem
cells of sufficient number to allow for a detailed analysis
of changes in gene expression.
Stem cells that infiltrate a brain infarct are believed to
synthesize and secrete growth and guidance factors that
are protective and orchestrate tissue recovery following
stroke. However, the epigenetic changes that occur in
these infiltrating stem cells due to environmental cues
produced by the ischemic insult remain poorly understood. The identification of genes that exhibit significantly altered expression by protective tissue-infiltrating
stem cells represents a powerful approach for discovery
of factors produced by stem cells that enable them to
mediate tissue restitution and repair following an ischemic stroke. Our analysis revealed that the expression of
a large number of genes is dramatically and persistently
increased in BMSC harvested from the ischemic infarct,
when compared to their 'naïve' (non-migrated) precursors. Interestingly, many of the genes whose messages
were most dramatically increased (> 100 fold) appear to
play important roles in neural patterning, remodeling,
adhesion and angiogenesis. Many other genes not previously associated with neuroprotection were also dramati-

Figure 7 Axon guidance KEGG pathway affected in BMSC isolated from ischemic brain. Genes affected represented in red.
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cally increased and these genes may play important
supporting roles in tissue recovery from stroke.
Different mechanisms have been proposed to explain
the improved neurological outcome following stem cell
treatment, including trans-differentiation into neural lineages, cell fusion, and neuroprotection through trophic
support. A role for neuroprotection mediated by released
trophic factors is supported by reports that describe the
wide array of neuroprotective factors released from stem
cells that could lead to improved neurological outcome
after stroke by promoting physiological responses such as
angiogenesis and/or neurogenesis, and inhibition of scar
formation. More direct support is provided by Qu and
coworkers[7], who identified, using gene microarray, the
factors secreted by BMSC after exposure to ischemic
brain extract. Their comparison of the gene expression
profiles between naive BMSC and ischemic extractexposed BMSC revealed an intense up-regulation of
genes that encode extracellular factors, such as fibroblast
growth factor-2, epidermal growth factor, nerve growth
factor-beta, insulin-like growth factor 1, VEGF-A, transforming growth factor, beta 1, and brain derived neurotrophic factor[7]. Our analysis of BMSC that infiltrate
post-ischemic brain tissue demonstrated gene activation
for most of the same trophic agents (Table S4, Additional
file 4). In our study, the expression of VEGF-A, VEGF-C
and TGF-beta were all increased in BMSC isolated from
post-ischemic brains, but these responses did not reach
statistical significance in the microarray assay. However,
consistent with previous reports[27], we found that
angiopoietin-1 and 4 were highly expressed in BMSC isolated from post-ischemic brains. Hence, our results provide strong support for the contention that within the
post-ischemic environment, BMSC release angiogenic
and neurotrophic factors that may mediate the neuroprotection observed following stem cell therapy.
Ddr2 (CD167b), a collagen adhesive receptor that participates in matrix integrin signaling[28], was increased
145-fold over naïve BMSC in our study, suggesting that
Ddr2 matrix signals may contribute to post-stroke
remodeling. ZIC-3 (Zinc finger protein-3) message was
increased 26-fold over naïve BMSC. ZIC-3, a member of
the C2H2-type zinc finger protein family, is a nuclear
transcription factor that functions in left-right body axis
alignment, and is a 'pluripotency' factor expressed during
cell regeneration[29]. Zic3 also interacts with BMP and
FGF signaling to direct neural cell programming[30]. We
also found that infiltrating BMSC expressed 195-fold
more cytokine receptor-like factor-1 (Crlf-1, cytokinelike factor 1, CLF-1, CRLM-3, cytokine receptor like molecule 3, NR6) transcript than naïve BMSC. CRLF1 forms
a heterodimeric complex with cardiotrophin-like
cytokine factor 1 (CLC-1), and the Crlf-1/CLC-1 heterodimer competes with ciliary neurotrophic factor for
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binding to the ciliary neurotrophic factor receptor
(CNTFR) complex. CrLF-1 is a cytokine ligand related to
IL-12 that supports differentiation and survival of a wide
range of neural cell types during embryonic development
and in adult neural tissues[31]. CrLF-1 mRNA is up-regulated by inflammatory cytokines e.g. TNF-α, IL-6, and
IFN-γ which are elevated in post-ischemic brain tissue[32].
Expression of FAM19A5 (also 'TAFA5') transcript was
elevated 164-fold in brain penetrating BMSC, compared
to naïve BMSC. FAM195 is a novel neuropeptide that is
highly expressed in the CNS, particularly in hypothalamic paraventricular nuclear vasopressin and oxytocin
cells[33]. FAM19a5 has been proposed to regulate brain
fluid balance, and elevated levels of TAFA5 may thus help
to control cerebral edema after stroke. Brain penetrating
stem cells were found to express 101-fold more transcript
for osteopontin (OPN) compared to naïve BMSC. OPN
and thrombin generated OPN-peptides have all been
shown to confer protection in stroke models[34,35]. Bayless has reported that OPN interacts with αvβ3 integrin
and binds endothelial and smooth muscle cells in an RGD
motif dependent manner[36]. OPN binding to α4β1 integrin has been implicated in the organization of endothelial cells in the developing vasculature, the extravasation
of immune cells into tissues, and the emigration of neuroblasts[37]. Fibroblast growth factor-7 (FGF7 or KGF),
which was increased 173-fold in our study, is known to
mediate cell proliferation and motility, protect against cell
death,[38] and has been shown to limit ischemia-induced
neuronal death[39]. We also found a 44-fold increase in
olfactomedin-1 (Olfm1), which has been implicated in
neuronal differentiation, axon extension and cell survival[40].
Several genes that are linked to the Wnt signaling pathway were also profoundly upregulated in infiltrating
BMSC. Glypican-1 (a GPI-anchored heparin sulfate proteoglycan) which interact with and suppresses hedgehog,
stimulates the Wnt pathway, and binds BMP and
FGF[41], exhibited a 155-fold increase. Dickkopf-2
(DKK2) expression was elevated 145-fold. Its homologue,
Dickkopf-1 is a Wnt antagonist that contributes to neuronal apoptosis following brain ischemia[42]; DKK1 has
been described as a target for treatment in neurodegenerative disorders e.g. beta-amyloid deposition, epilepsy,
excitotoxicity. While DKK-1, (and Dkk4) block Wnt signaling, DKK2 and DKK3 do not,[43] and in some systems
DKK2 actually synergizes with Wnt signals[44,45].
Therefore, in the setting of stroke recovery, elevated levels of secreted DKK2 might limit neuronal apoptosis to
preserve neuron survival and improve tissue integrity.
Sushi-repeat containing protein (SRPX2), a ligand for
urokinase-type plasminogen activator that interacts with
cathepsins B and ADAMTS4 to control extracellular
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matrix remodeling[46], was elevated 33-fold in infiltrating BMSC compared naïve BMSC. SRPX2 participates in
cell migration and adhesion through regulation of FAK
phosphorylation[47]. It also contributes to the modulation of endothelial remodeling in angiogenesis[48], which
may be a factor in the enhanced cerebral angiogenesis
that is associated with stem cell therapy in ischemic brain
disorders.
Several gene messages were found to be highly suppressed in BMSC isolated from the ischemic brain.
Among these, basonuclin (Bnc1), a zinc-finger protein
that is highly expressed in early keratinocytes[49], was
down regulated 523-times. Down-regulation of this message may indicate a change in cell lineage fate within the
ischemic environment. Glycoprotein m6a (Gpm6a)
expression (reduced 157-fold) is associated with neuronal
development and migration, and high levels of Gpm6a in
stem cells has been linked to enhanced neuronal cell differentiation and migration[50]. We also noted a 34-fold
suppression of breast cancer 1 gene (Brca1), a nuclear
phosphoprotein that plays a role in maintaining genomic
stability and in tumor suppression. Brca1 has been implicated in preventing apoptosis in early neuronal progenitors[51] and its expression in adult life is associated with
Alzheimer's disease[52]. Smpd3 (reduced 24-fold) catalyzes the hydrolysis of sphingomyelin to form ceramide
and phosphocholine. Ceramide mediates apoptosis and
regulates the cell cycle by acting as a growth suppressor
in confluent cells. Smpd3 also mediates cellular responses
to IL-1ß and TNFα [53]. Tetraspanin 8 (Tspan8 or
Tm4sf3) (reduced 23-fold), a member of the transmembrane 4 superfamily, is known to mediate signal transduction events that contribute to the regulation of cell
development, activation, growth and motility[54]. Replication factor C (Rfc4) (9-fold reduction), which is
required in the elongation of primed DNA templates by
DNA polymerase δ and DNA polymerase ε[55], is believe
to ensure error-free proliferation of stem cells at early
phases of cell growth.
Astrocytes form glial scars along ischemic lesions and
produce proteoglycans that inhibit axonal growth[56].
Suppression of inhibitory factors by cell-based therapies
leads to axonal growth that correlate with improved functional outcome after stroke[57]. For example, it has been
reported that bone-marrow mesenchymal cells reduce
the expression of axonal-growth inhibitory proteins that
are released by astrocytes, thereby allowing axon formation in the ischemic brain[58]. In our study, BMSC harvested from post-ischemic brain tissue exhibited a
persistent and altered expression of several of genes that
have been implicated in the regeneration and guidance of
axons (Figure 7). Among these genes, Robo-1, EphA4,
Pak1 and SLIT-Robo RhoGTPase activating protein
exhibited the most significant up-regulation, while the
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expression of semaphorin 3D and ephrin-B1 were significantly reduced. These findings support the role of BMSC
re-programming in axon formation and guidance following ischemic stroke.
Several studies suggest that stem cells can also attenuate immune responses of the host[59-61]. Supporting this
view are changes in gene expression related to immune
processes in human BMSC transplanted into the mouse
hippocampus 1 day after global ischemia[9]. The transplanted BMSC exhibited a change in gene ontology
groups for carbohydrate binding, cell adhesion, basement
membrane as well as antigen presentation and processing. The results of our analysis suggest that the changes in
immune-related gene processes were small in the BMSC
that infiltrate ischemic brain tissue, particularly in comparison with the responses noted for genes related to
axon guidance, MAPK pathway and the cell cycle. While
an explanation for the different gene expression
responses between the two studies is not readily apparent, it may result from differences in ischemic model,
route of administration of BMSC, and/or brain region
studied.

Conclusions
In conclusion, using a novel approach for BMSC isolation
from postischemic brain tissue, we found that BMSC
assume a new and very different genetic profile that
favors the secretion of numerous extracellular factors
into ischemic brain tissue that have the potential to facilitate neuroprotective responses such as angiogenesis, and
axonal guidance and regeneration. Our findings may help
to explain the neuroprotective effects previously proposed for stem cells in ischemic stroke.
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